Pharvaris

Pharvaris is a late-stage biopharmaceutical company focused on developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. They are a leader in bradykinin-mediated diseases and are committed to providing patients with choice by offering effective, safe, and easy-to-administer therapies. Their lead candidate, deucrictibant, is a potent, oral small-molecule bradykinin B2 receptor antagonist currently in clinical development for both on-demand and prophylactic treatment of HAE attacks. Pharvaris is advancing two distinct formulations of deucrictibant: an immediate-release capsule for on-demand treatment and an extended-release tablet for prophylaxis.

With positive data from Phase 2 studies in both on-demand and prophylactic treatment settings, Pharvaris is moving towards pivotal Phase 3 studies to confirm the potential of deucrictibant as a game-changer in HAE management. The company's commitment to patient needs and their focus on developing convenient oral alternatives are key drivers in their mission to improve the lives of people living with HAE.

Pharvaris offers a flexible, hybrid work environment, allowing employees to choose where and, to some extent, when they work. While most roles offer flexibility, the Office Manager US & Executive Assistant position requires a regular presence of at least 2-3 days a week in the Lexington office due to the responsibilities involved.

Pharvaris offers employees a flexible (hybrid) working environment, allowing them to choose where and, to some extent, when they work. They are also part of a dedicated and caring team, have the opportunity to contribute freely, and experience short and informal lines of communication.

Pharvaris is a clinical-stage biopharmaceutical company dedicated to developing innovative, oral treatments for hereditary angioedema (HAE). Their mission is to improve the standard of care for people living with HAE by providing effective, safe, and easy-to-administer oral alternatives to injected therapies. By targeting the bradykinin B2 receptor with novel small molecules, Pharvaris aims to empower individuals with HAE to live normal lives free from the burden of frequent attacks and the limitations of current treatment options.

Pharvaris promotes a culture built on core values of considering others carefully, leading with trust, ensuring rigor and diversity of thought, and contributing freely. They foster a flexible hybrid work environment where employees can choose their work location and hours to some extent. They emphasize short and informal lines of communication and are driven by individuals passionate about developing breakthrough therapies that impact people's lives.

Pharvaris fosters a culture of diversity, equity, and inclusion by valuing and respecting individual differences. They prioritize considering all those impacted by their mission, leading with trust, ensuring rigorous decision-making with diverse perspectives, and promoting freedom of contribution, ensuring everyone feels heard. This commitment is reflected in their company values and reflected in their dedication to building a team of diverse and dedicated individuals.